Zoetis Net Income 2011-2024 | ZTS

Zoetis net income for the twelve months ending September 30, 2024 was $2.430B, a 6.58% increase year-over-year.

  • Zoetis annual net income for 2023 was $2.344B, a 10.88% increase from 2022.
  • Zoetis annual net income for 2022 was $2.114B, a 3.78% increase from 2021.
  • Zoetis annual net income for 2021 was $2.037B, a 24.36% increase from 2020.

Zoetis Net Income 2011-2024 | ZTS

  • Zoetis annual net income for 2023 was $2.344B, a 10.88% increase from 2022.
  • Zoetis annual net income for 2022 was $2.114B, a 3.78% increase from 2021.
  • Zoetis annual net income for 2021 was $2.037B, a 24.36% increase from 2020.
Related Stocks
Company NameMarket
Cap
Takeda Pharmaceutical (TAK)$43.9B
Merck (MKKGY)$20.8B
Astellas Pharma (ALPMY)$20.2B
Sandoz Group AG (SDZNY)$19.6B
United Therapeutics (UTHR)$17.7B
Summit Therapeutics (SMMT)$15.4B
Neurocrine Biosciences (NBIX)$12.7B
Shionogi (SGIOY)$12.3B
Catalent (CTLT)$10.9B
Madrigal Pharmaceuticals (MDGL)$7.4B
Jazz Pharmaceuticals (JAZZ)$6.9B
Orion OYJ (ORINY)$6.8B
Ionis Pharmaceuticals (IONS)$5.7B
Corcept Therapeutics (CORT)$5.7B
Crinetics Pharmaceuticals (CRNX)$4.7B
PTC Therapeutics (PTCT)$3.3B
Dyne Therapeutics (DYN)$3B
Catalyst Pharmaceuticals (CPRX)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Soleno Therapeutics (SLNO)$2.2B
NewAmsterdam Pharma (NAMS)$2B
Recursion Pharmaceuticals (RXRX)$2B
Centessa Pharmaceuticals (CNTA)$1.8B
Harrow (HROW)$1.7B
Ocular Therapeutix (OCUL)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.6B
Xencor (XNCR)$1.6B
Ardelyx (ARDX)$1.5B
ARS Pharmaceuticals (SPRY)$1.5B